ArticleInvestigational new drugs2017

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Monica Mita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.